Clinical Trials Logo

Relapse/Recurrence clinical trials

View clinical trials related to Relapse/Recurrence.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04749355 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Start date: November 14, 2021
Phase: Phase 2
Study type: Interventional

An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20 adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study. Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients will be followed for 1 year in the study and additional 1 year post study follow-up.